Pharma BD Deal Intelligence
Sanofi and Teva entered a global co-development and co-commercialization collaboration for duvakitug (TEV'574 / TEV-48574), a then-Phase 2b anti-TL1A monoclonal antibody for IBD, announced October 4, 2023 (closed November 30, 2023). Teva received $500M upfront and is eligible for up to $1.0B in development/launch milestones, with equal cost/profit share in major markets and royalties elsewhere; Sanofi leads Phase 3 and commercializes in North America, Japan and most of the world while Teva commercializes in Europe, Israel and select markets. The bet has so far been validated: on December 17, 2024 the Phase 2b RELIEVE UCCD basket study met its primary endpoints in both ulcerative colitis (47.8% high-dose clinical remission vs 20.45% placebo at week 14) and Crohn's disease (47.8% high-dose endoscopic response vs 13.0% placebo), with the partners claiming best-in-class potential and a clean safety profile. Durable maintenance (week 44) data reported at ECCO 2025 and on February 17, 2026 reinforced the profile. Sanofi initiated the Phase 3 program in IBD in late 2025 (induction study NCT07184996 and maintenance study NCT07185009, both recruiting; induction actual start October 8, 2025).